leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These may include increased production of tumor resistance conferring proteins such as multidrug resistance (MDR-1) and myeloid cell leukemia (MCL-1).
|
30452910 |
2019 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of leukaemia cells with 3p-siRNA-MDR1 down-regulated MDR1 expression, reduced-drug resistance and induced immune and pro-apoptotic effects in drug-resistant HL-60/Adr and K562/Adr human leukaemia cell lines.
|
28380403 |
2017 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytotoxic studies have demonstrated a higher sensitivity of the leukemia lines to DOX-BNNPs compared with the carcinoma lines: IC<sub>50</sub>(DOX-BNNPs) is 1.13, 4.68, 0.025, and 0.14 μg/mL for the KB-3-1, MDR KB-8-5, K562, and MDR i-S9 cell lines, respectively.
|
28857548 |
2017 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between the MDR1 G2677T polymorphism and leukemia risk was conducted by odds ratios (ORs) and 95% confidence intervals (95% CI).
|
24142546 |
2014 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the MDR1 C3435T polymorphism associate with risk of leukaemia.
|
23731124 |
2013 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bortezomib is a promising potential therapy for acute leukemia, especially mdr1 drug-resistant leukemia.
|
22145750 |
2012 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings provide further evidence that the MDR1 C3435T variant may modify the susceptibility to leukemia.
|
22088099 |
2012 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, it had no effect on P-glycoprotein-mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells and multidrug resistance-related protein 1-mediated doxorubicin resistance in MRP1-transfected human epidermoid cancer KB-3-1 cells.
|
21566063 |
2011 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have identified a novel MDR1 (GT1292-3TG) (Cys431Leu) genetic variation through systematic profiling of subjects with leukemia.
|
20623213 |
2010 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, these results suggested that the MDR1 TT genotype might influence risk of development of acute lympoblastic leukemia and the CC genotype might be linked to a poor prognosis of ALL.
|
21133625 |
2010 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The process behind the expression of mdr-1/P-gp and mrp/MRP in human leukemia/lymphoma.
|
19414348 |
2009 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this report, we describe a novel G571A variant of MDR1 detected in 6.4% of leukemia patients.
|
18723777 |
2008 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The multidrug resistance gene, MDR1, is one of the genes responsible for resistance to chemotherapy in the treatment of leukaemia and other cancers.
|
17909680 |
2007 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the tumor-bearing nude mice, anti-tumor drugs vincristine, daunorubicin (DNR), STI571, and STI571 plus VCR for the treatment of mdr1 and bcr/abl double positive leukemia were studied respectively.
|
16780770 |
2006 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We recently discovered a novel G --> T variant at 1199 nucleotide position of MDR1 which exhibits a 2.3% allelic frequency in leukemia patients.
|
16917872 |
2006 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.
|
16566920 |
2006 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings indicate that siRNA specifically and efficiently interferes with the expression of mdr1 and could be used as a molecularly defined therapeutic approach for MDR in the treatment of leukemia.
|
15375375 |
2004 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06.
|
15294454 |
2004 |
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In this review, we cover the current information and postulate that epigenetic modification of MDR1 chromatin influences gene transcription in leukaemia.
|
14567978 |
2003 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
|
12609962 |
2003 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
P-glycoprotein (P-gp)/multi-drug resistance 1 (MDR1) gene is recognized to be, at least in part, responsible for the refractoriness to chemotherapy of leukemia.
|
11734301 |
2002 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To overcome P-gp-mediated drug resistance, we have developed six anti-MDR1 hammerhead ribozymes and delivered them to P-gp-overproducing human leukemia cell line by a retroviral vector containing RNA polymerase III promoter.
|
11774737 |
2001 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MDR1 expression rate was significantly correlated with factors such as a history of preceding chemotherapy, elder age of the patient, and certain disease types (eg, leukemia progressed from myelodysplastic syndrome).
|
10695666 |
2000 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although innumerable reports have been published in which P-gp has been shown to confer MDR to malignant (including leukemia) cells, so far, large-scale studies in the clinical setting have not convincingly proven that MDR1 plays a major role in clinical drug resistance when the influence of other known prognostic factors in human leukemia are taken into account.
|
11185984 |
2000 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Retroviral vector transduction of human leukemia cell lines expressing MDR1 was accomplished by co-culturing these with virus producer cells.
|
10362143 |
1999 |